Status:
COMPLETED
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study tr...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- metastatic pancreatic cancer (adenocarcinoma);
- good liver, kidney, and bone marrow function.
Exclusion
- previous systemic treatment for metastatic pancreatic cancer;
- pregnant or lactating females;
- fertile men, or women of childbearing potential, not using adequate contraception;
- major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;
- current or recent treatment (within 30 days prior to starting study treatment) with another investigational drug, or participation in another investigational study.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
607 Patients enrolled
Trial Details
Trial ID
NCT01214720
Start Date
July 1 2005
End Date
October 1 2008
Last Update
August 13 2014
Active Locations (101)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide, Australia, 5011
2
Camperdown, Australia, 2050
3
Footscray, Australia, 3011
4
Heidelberg, Australia, 3084